Topics

Tightening the tumor-targeting abilities of checkpoint blockade immunotherapy

20:00 EDT 11 Jul 2019 | AAAS

(American Association for the Advancement of Science) Seeking to improve upon existing checkpoint inhibitor therapies, scientists have developed a common checkpoint inhibitor (anti-PD-L1) in a nanoparticle formulation, which were activated specifically at tumor sites in mouse models of cancer.

Original Article: Tightening the tumor-targeting abilities of checkpoint blockade immunotherapy

NEXT ARTICLE

More From BioPortfolio on "Tightening the tumor-targeting abilities of checkpoint blockade immunotherapy"

Quick Search

Relevant Topic

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...